Flavaglines alleviate doxorubicin cardiotoxicity: Implication of Hsp27

30Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Background: Despite its effectiveness in the treatment of various cancers, the use of doxorubicin is limited by a potentially fatal cardiomyopathy. Prevention of this cardiotoxicity remains a critical issue in clinical oncology. We hypothesized that flavaglines, a family of natural compounds that display potent neuroprotective effects, may also alleviate doxorubicin-induced cardiotoxicity. Methodology/Principal Findings: Our in vitro data established that a pretreatment with flavaglines significantly increased viability of doxorubicin-injured H9c2 cardiomyocytes as demonstrated by annexin V, TUNEL and active caspase-3 assays. We demonstrated also that phosphorylation of the small heat shock protein Hsp27 is involved in the mechanism by which flavaglines display their cardioprotective effect. Furthermore, knocking-down Hsp27 in H9c2 cardiomyocytes completely reversed this cardioprotection. Administration of our lead compound (FL3) to mice attenuated cardiomyocyte apoptosis and cardiac fibrosis, as reflected by a 50% decrease of mortality. Conclusions/Significance: These results suggest a prophylactic potential of flavaglines to prevent doxorubicin-induced cardiac toxicity. © 2011 Bernard et al.

Cite

CITATION STYLE

APA

Bernard, Y., Ribeiro, N., Thuaud, F., Türkeri, G., Dirr, R., Boulberdaa, M., … Désaubry, L. (2011). Flavaglines alleviate doxorubicin cardiotoxicity: Implication of Hsp27. PLoS ONE, 6(10). https://doi.org/10.1371/journal.pone.0025302

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free